Zinc Supplementation in Patients With β-Thalassemia Major Complicated With Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03851055|
Recruitment Status : Completed
First Posted : February 22, 2019
Last Update Posted : February 25, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Beta-thalassemia represents a group of recessive inherited hemoglobin disorders characterized by reduced synthesis of β-globin chain. The homozygous state (β-thalassemia major) "TM" results in severe anemia, which needs regular blood transfusion . The life expectancy in patients with TM has increased due to therapeutically management, such as frequent transfusion, desferal administration and bone marrow transplantation. Diabetes is clinically characterized by hyperglycemia due to either low circulating concentrations of, or decreased sensitivity to, insulin. Patients with TM typically exhibit β-cell or insulin insufficiency, and may develop diabetes due to toxic levels of iron in their pancreas, one of the strongest predictors of β-cell destruction. By contrast, hyperinsulinemia, secondary to insulin resistance, with normal glucose tolerance has also been observed.
The pathogenic mechanisms leading from siderosis to diabetes are poorly understood.
|Condition or disease||Intervention/treatment||Phase|
|Beta-thalassemia Major Complicated With Diabetes||Drug: Zinc||Phase 3|
Zinc(Zn) is a critical trace element in human health. Zinc has a potential to be utilized for the treatment of type 2 diabetes; however, evidence suggests that the effect of Zn on type 2 diabetes remains unclear. Up to 85% of the whole body Zn content is found in muscle and bones, with 11% in the skin and liver .Zn is an indispensable co-factor for more than 300 enzymes involved in metabolism and also reportedly plays a role in aging, immune system, apoptosis, and oxidative stress.
Although the effect of zinc supplementation in the improvement of oxidative stress is controversial, one of the causes that the oxidative stress is present in patients with type 2 diabetes is the change in zinc metabolism. Recent studies have demonstrated that the islet-restricted zinc transporter, ZnT8 (SLC30A8), regulates insulin secretion and hepatic insulin clearance, suggesting that Zn is a key biological factor in glucose homeostasis and the risk of developing type 2 diabetes.
In patients without thalassemia, there is a rich body of literature focused on the "diabetogenic effects" of altered zinc status.
Zinc supplementation has even been suggested as an adjunct therapy in the management of non-thalassemia related diabetes .Functional zinc deficiency exists in a contemporary sample of healthy β-thalassemic patients. An estimated 20% to 30% of patients with β-thalassemia are zinc deficient. The high prevalence is thought to be related to a combination of increased urinary losses compounded by elevated requirements.
Glucose homeostasis and its relation to Zinc status has not been widely studied especially in Egyptian children and adolescents with β-thalassemia major.
The aim of this study is to:
- Assess zinc status in patients with β-thalassemia major and diabetes mellitus and its relation to clinical and laboratory parameters of these patients.
- Effect of zinc supplementation on glucose homeostasis in patients with β-thalassemia major and diabetes mellitus.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Effect of Zinc Supplementation on Glucose Homeostasis in Patients With β-Thalassemia Major Complicated With Diabetes Mellitus|
|Actual Study Start Date :||August 1, 2017|
|Actual Primary Completion Date :||July 10, 2018|
|Actual Study Completion Date :||August 28, 2018|
Active Comparator: intervention group
will receive zinc supplementation
One arm will receive Zinc Second arm will receive placebo
No Intervention: Control group
Patients will receive placebo only
- Fasting blood glucose mg/dl [ Time Frame: 12 weeks ]the change in fasting blood glucose level after the 12 weeks of treatment in the intervention group when compared to the placebo group.
- HbA1c% [ Time Frame: 12 weeks ]changes in HbA1c% levels
- fructosamine mg/dl [ Time Frame: 12 weeks ]changes in fructosamine levels mg/dl
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||10 Years to 18 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Gender Based Eligibility:||Yes|
|Accepts Healthy Volunteers:||No|
- Patients with β-thalassemia major and diabetes confirmed by history, examination and investigation.
- Patients on regular visits to clinic.
- Age more than 10 years old.
- Those who refused to lay informed consent.
- Those below age limit.
- Patients with other disorders that may affect glucose homeostasis rather than TM.
- Patients with autoimmune disease, collagen diseases, infections, tumors, hematological diseases other than Thalassemia major.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03851055
|Cairo, Egypt, 11361|
|Responsible Party:||Nancy Samir Elbarbary, Professor of Pediatrics, Ain Shams University|
|Other Study ID Numbers:||
Ain shams Pediatrics 3082019
|First Posted:||February 22, 2019 Key Record Dates|
|Last Update Posted:||February 25, 2019|
|Last Verified:||February 2019|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Plan Description:||Patients data and identity are totally anonymous to the study group|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Glucose Metabolism Disorders
Endocrine System Diseases
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn